Back to search

Article

Pembrolizumab combined with Axitinib in ASPSCR1-TFE3 gene fusion translocation renal cell carcinoma: a case report and literature review

2022-10-06

Abstract excerpt

<h4>Background: </h4> Translocation renal cell carcinoma (tRCC) is a subtype of nccRCC driven by MiT/TFE gene fusion. The demographic characteristics of tRCC include younger age at diagnosis, later staging at diagnosis, high degree of malignancy, poor prognosis, and female majority. There are currently no standard guidelines for the diagnosis and treatment of this type of kidney cancer. <h4>Objective:</h4> To inve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e6bcc509-4680-5966-ab57-99bf6d4b3a3a
DOI
10.21203/rs.3.rs-2101971/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pembrolizumab combined with Axitinib in ASPSCR1-TFE3 gene fusion translocation renal cell carcinoma: a case report and literature reviewDOI 10.21203/rs.3.rs-2101971/v1
Select a neighboring publication to make it the new centre.